Đang chuẩn bị liên kết để tải về tài liệu:
Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): An open-label, non-randomized, multicenter, phase IV clinical trial
Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Erlotinib is approved for the first line treatment of epidermal growth factor receptor (EGFR) mutationpositive non-small cell lung cancer. Since the number of prospective studies in Caucasian patients treated in routine clinical setting is limited we conducted a multicenter, phase IV clinical trial to determine the efficacy and safety of erlotinib and to demonstrate the feasibility of the validated standardized companion diagnostic method of EGFR mutation detection. | Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma CEETAC An open-label non-randomized multicenter phase IV clinical trial